Zydus rolls out ADC biosimilar Ujvira to treat breast cancer
Zydus claims that Ujvira is the world’s first biosimilar antibody-drug conjugate of trastuzumab emtansine and will be offered…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 May 21
Zydus claims that Ujvira is the world’s first biosimilar antibody-drug conjugate of trastuzumab emtansine and will be offered…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 May 21
GSK and Innoviva have jointly developed Trelegy Ellipta, Relvar Ellipta, and Anoro Ellipta drugs for use in asthma…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 May 21
The new cGMP facility will be designed to provide an end-to-end solution to advance cell therapy development and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 May 21
Kuur’s NKT cell platform technology will help Athenex to expand its cell therapy development capabilities
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Apr 21
The acquisition follows Pfizer’s initial equity investment in Amplyx, as part of the antifungal therapies developer's Series C…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Apr 21
Adagio will use the funding to advance its lead candidate ADG20, a single agent intended for both treatment…
Active Pharmaceutical Ingredients and IntermediatesPharmaceuticals
08 Apr 21
Trodelvy is an antibody and topoisomerase inhibitor conjugate that targets Trop-2 receptor, a protein often expressed in epithelial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Apr 21
With the acquisition, Piramal will benefit from Hemmo’s peptide API development and manufacturing capabilities
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Mar 21
Rodeo’s preclinical programme targeting 15-PGDH will support Amgen in developing therapeutic agents against inflammatory disease indications
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Mar 21
AbbVie has acquired the portfolio of women's drugs as part of its $63bn acquisition of Allergan, completed last…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates